(3,4-dimethoxyphenyl)-[1-(2-phenylethyl)-3-piperidinyl]methanone is a complex chemical compound. Its importance lies in its potential **pharmacological properties** and its use as a **research tool**.
Let's break it down:
**Chemical Structure:**
* **(3,4-dimethoxyphenyl)** refers to a benzene ring with two methoxy groups (-OCH3) attached at the 3rd and 4th positions.
* **[1-(2-phenylethyl)-3-piperidinyl]** describes a piperidine ring with:
* A phenylethyl group (C6H5CH2CH2-) attached to the 1st position.
* A ketone group (-C=O) attached to the 3rd position.
* **methanone** simply indicates the presence of a ketone group.
**Pharmacological Properties:**
This compound has been studied as a potential **antidepressant**. It is believed to work by interacting with **serotonin receptors**, particularly the **5-HT1A receptor**, which is known to play a role in mood regulation.
**Research Significance:**
* **Understanding Serotonin Receptor Function:** Studying the effects of this compound on serotonin receptors can provide valuable insights into how these receptors function and contribute to depression.
* **Development of Novel Antidepressants:** The research on this compound could lead to the development of new and more effective antidepressants that specifically target serotonin receptors.
* **Understanding the Role of Chemical Structure in Pharmacological Activity:** Analyzing the structure-activity relationships of this compound and its derivatives can help researchers understand how specific chemical features influence their pharmacological effects.
**Important Note:** This compound is still under investigation and has not yet been approved for clinical use as an antidepressant. Further research is needed to evaluate its safety, efficacy, and potential side effects.
In summary, (3,4-dimethoxyphenyl)-[1-(2-phenylethyl)-3-piperidinyl]methanone is a complex chemical compound with potential antidepressant activity. It serves as a research tool for understanding serotonin receptor function and developing new treatment options for depression.
| ID Source | ID |
|---|---|
| PubMed CID | 44629410 |
| CHEMBL ID | 1794269 |
| CHEBI ID | 91487 |
| Synonym |
|---|
| BRD-A02809788-001-01-5 |
| smr001600585 |
| MLS002729074 |
| CHEMBL1794269 |
| CHEBI:91487 |
| (3,4-dimethoxyphenyl)-[1-(2-phenylethyl)-3-piperidinyl]methanone |
| Q27163325 |
| Class | Description |
|---|---|
| aromatic ketone | A ketone in which the carbonyl group is attached to an aromatic ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 23.7246 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Vpr | Human immunodeficiency virus 1 | Potency | 28.1838 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 89.1251 | 3.9811 | 46.7448 | 112.2020 | AID720708 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| guanyl-nucleotide exchange factor activity | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| protein binding | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| cAMP binding | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| protein-macromolecule adaptor activity | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| small GTPase binding | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytosol | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| plasma membrane | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| membrane | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| hippocampal mossy fiber to CA3 synapse | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| plasma membrane | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID631974 | Antitrypanosomal activity against trypomastigote form of Trypanosoma cruzi Tulahuen expressing beta-galactosidase infected in mouse NIH/3T3 cells assessed as inhibition of parasite replication after 4 days by betagalactosidase-based luminescence assay | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23 | Identification of small-molecule inhibitors of Trypansoma cruzi replication. |
| AID631977 | Selectivity ratio of IC50 for mouse NIH/3T3 cells to IC50 for trypomastigote form of Trypanosoma cruzi Tulahuen | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23 | Identification of small-molecule inhibitors of Trypansoma cruzi replication. |
| AID631978 | Solubility of compound in phosphate buffered saline buffer | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23 | Identification of small-molecule inhibitors of Trypansoma cruzi replication. |
| AID631975 | Cytotoxicity against mouse NIH/3T3 cells | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23 | Identification of small-molecule inhibitors of Trypansoma cruzi replication. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||